SUMO conjugation - A mechanistic view

Biomolecular Concepts

Volumn 8, Issue 1, 2017, Pages 13-36

  Pichler, Andrea ^a   Fatouros, Chronis ^a   Lee, Heekyoung ^a   Eisenhardt, Nathalie ^a  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

E1; E2; E3 enzymes; SIM; SUMO chains; SUMO paralogs

Indexed keywords

SUMO 1 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ENZYME SPECIFICITY; METABOLISM; SUMOYLATION;

SUBSTRATE SPECIFICITY; SUMO-1 PROTEIN; SUMOYLATION; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 85015602887     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc-2016-0030     Document Type: Review

References (209)

1. Droescher M, Chaugule VK, Pichler A. SUMO rules: regulatory concepts and their implication in neurologic functions. Neuromol Med 2013; 15: 639-60.
2. Nie M, Boddy MN. Cooperativity of the SUMO and Ubiquitin Pathways in Genome Stability. Biomolecules 2016; 6: 14.
3. Chymkowitch P, Nguea PA, Enserink JM. SUMO-regulated transcription: challenging the dogma. Bioessays 2015; 37: 1095-105.
4. Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 2013; 82: 357-85.
5. Cubenas-Potts C, Matunis MJ. SUMO: a multifaceted modifier of chromatin structure and function. Dev Cell 2013; 24: 1-12.
6. Geoffroy MC, Hay RT. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 2009; 10: 564-8.
7. Garcia-Rodriguez N, Wong RP, Ulrich HD. Functions of ubiquitin and SUMO in DNA replication and replication stress. Front Genet 2016; 7: 87.
8. Eifler K, Vertegaal AC. SUMOylation-mediated regulation of cell cycle progression and cancer. Trends Biochem Sci 2015; 40: 779-93.
9. Mattoscio D, Segre CV, Chiocca S. Viral manipulation of cellular protein conjugation pathways: the SUMO lesson. World J Virol 2013; 2: 79-90.
10. Guo B, Yang SH, Witty J, Sharrocks AD. Signalling pathways and the regulation of SUMO modification. Biochem Soc Trans 2007; 35(Pt 6): 1414-8.
11. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002; 419: 135-41.
12. Pfander B, Moldovan GL, Sacher M, Hoege C, Jentsch S. SUMOmodified PCNA recruits Srs2 to prevent recombination during S phase. Nature 2005; 436: 428-33.
13. Hendriks IA, Vertegaal AC. A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol 2016; 17: 581-95.
14. Cubenas-Potts C, Srikumar T, Lee C, Osula O, Subramonian D, Zhang XD, Cotter RJ, Raught B, Matunis MJ. Identification of SUMO-2/3-modified proteins associated with mitotic chromosomes. Proteomics 2015; 15: 763-72.
15. Hendriks IA, D'Souza RC, Yang B, Verlaan-de Vries M, Mann M, Vertegaal AC. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 2014; 21: 927-36.
16. Henley JM, Craig TJ, Wilkinson KA. Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction. Physiol Rev 2014; 94: 1249-85.
17. Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, Kelstrup CD, Francavilla C, Medema RH, Olsen JV. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell 2014; 53: 1053-66.
18. Dantuma NP, Pfeiffer A. Real estate in the DNA damage response: ubiquitin and SUMO ligases home in on DNA doublestrand breaks. Front Genet 2016; 7: 58.
19. Lee YJ, Mou Y, Maric D, Klimanis D, Auh S, Hallenbeck JM. Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One 2011; 6: e25852.
20. Chen SF, Gong C, Luo M, Yao HR, Zeng YJ, Su FX. Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer 2011; 30: 638-44.
21. Du L, Li YJ, Fakih M, Wiatrek RL, Duldulao M, Chen Z, Chu P, Garcia-Aguilar J, Chen Y. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nat Commun 2016; 7: 12326.
22. Moschos SJ, Mo YY. Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol 2006; 37: 309-19.
23. Qin Y, Bao H, Pan Y, Yin M, Liu Y, Wu S, Li H. SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma. Mol Med Rep 2014; 9: 877-81.
24. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010; 29: 1763-72.
25. Eckermann K. SUMO and Parkinson's disease. Neuromolecular Med 2013; 15: 737-59.
26. Martins WC, Tasca CI, Cimarosti H. Battling alzheimer's disease: targeting SUMOylation-mediated pathways. Neurochem Res 2016; 41: 568-78.
27. Mendler L, Braun T, Muller S. The ubiquitin-like SUMO system and heart function: from development to disease. Circ Res 2016; 118: 132-44.
28. Sireesh D, Bhakkiyalakshmi E, Ramkumar KM, Rathinakumar S, Jennifer PS, Rajaguru P, Paulmurugan R. Targeting SUMOylation cascade for diabetes management. Curr Drug Targets 2014; 15: 1094-106.
29. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol 2012; 13: 755-66.
30. Nayak A, Muller S. SUMO-specific proteases/isopeptidases: SENPs and beyond. Genome Biol 2014; 15: 422.
31. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009; 10: 319-31.
32. Lois LM, Lima CD. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J 2005; 24: 439-51.
33. Wang J, Taherbhoy AM, Hunt HW, Seyedin SN, Miller DW, Miller DJ, Huang DT, Schulman BA. Crystal structure of UBA2(ufd)-Ubc9: insights into E1-E2 interactions in Sumo pathways. PLoS One 2010; 5: e15805.
34. Mahajan R, Gerace L, Melchior F. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J Cell Biol 1998; 140: 259-70.
35. Matunis MJ, Coutavas E, Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 1996; 135: 1457-70.
36. Johnson ES, Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J Biol Chem 1997; 272: 26799-802.
37. Bayer P, Arndt A, Metzger S, Mahajan R, Melchior F, Jaenicke R, Becker J. Structure determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol 1998; 280: 275-86.
38. Hendriks IA, Lyon D, Young C, Jensen LJ, Vertegaal AC, Nielsen ML. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol 2017. doi: 10.1038/nsmb.3366.
39. Evdokimov E, Sharma P, Lockett SJ, Lualdi M, Kuehn MR. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. J Cell Sci 2008; 121(Pt 24): 4106-13.
40. Zhang FP, Mikkonen L, Toppari J, Palvimo JJ, Thesleff I, Janne OA. Sumo-1 function is dispensable in normal mouse development. Mol Cell Biol 2008; 28: 5381-90.
41. Wang L, Wansleeben C, Zhao S, Miao P, Paschen W, Yang W. SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development. EMBO Rep 2014; 15: 878-85.
42. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitinrelated protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000; 275: 6252-8.
43. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004; 279: 27233-8.
44. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837-41.
45. Liang YC, Lee CC, Yao YL, Lai CC, Schmitz ML, Yang WM. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies. Sci Rep 2016; 6: 26509.
46. Su HL, Li SS. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002; 296: 65-73.
47. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 2001; 276: 35368-74.
48. Wei W, Yang P, Pang J, Zhang S, Wang Y, Wang MH, Dong Z, She JX, Wang CY. A stress-dependent SUMO4 sumoylation of its substrate proteins. Biochem Biophys Res Commun 2008; 375: 454-9.
49. Ullmann R, Chien CD, Avantaggiati ML, Muller S. An acetylation switch regulates SUMO-dependent protein interaction networks. Mol Cell 2012; 46: 759-70.
50. Lin CH, Liu SY, Lee EH. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene 2016; 35: 595-607.
51. Bursomanno S, Beli P, Khan AM, Minocherhomji S, Wagner SA, Bekker-Jensen S, Mailand N, Choudhary C, Hickson ID, Liu Y. Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells. DNA Repair (Amst) 2015; 25: 84-96.
52. Impens F, Radoshevich L, Cossart P, Ribet D. Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc Natl Acad Sci USA 2014; 111: 12432-7.
53. Lamoliatte F, Caron D, Durette C, Mahrouche L, Maroui MA, Caron-Lizotte O, Bonneil E, Chelbi-Alix MK, Thibault P. Largescale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling. Nat Commun 2014; 5: 5409.
54. Tammsalu T, Matic I, Jaffray EG, Ibrahim AF, Tatham MH, Hay RT. Proteome-wide identification of SUMO2 modification sites. Sci Signal 2014; 7: rs2.
55. Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002; 108: 345-56.
56. Yunus AA, Lima CD. Lysine activation and functional analysis of E2-mediated conjugation in the SUMO pathway. Nat Struct Mol Biol 2006; 13: 491-9.
57. Matic I, Schimmel J, Hendriks IA, van Santen MA, van de Rijke F, van Dam H, Gnad F, Mann M, Vertegaal AC. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol Cell 2010; 39: 641-52.
58. Yang SH, Galanis A, Witty J, Sharrocks AD. An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J 2006; 25: 5083-93.
59. Hietakangas V, Anckar J, Blomster HA, Fujimoto M, Palvimo JJ, Nakai A, Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci USA 2006; 103: 45-50.
60. Mohideen F, Capili AD, Bilimoria PM, Yamada T, Bonni A, Lima CD. A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nat Struct Mol Biol 2009; 16: 945-52.
61. Picard N, Caron V, Bilodeau S, Sanchez M, Mascle X, Aubry M, Tremblay A. Identification of estrogen receptor beta as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3b. Mol Cell Biol 2012; 32: 2709-21.
62. Pichler A, Knipscheer P, Oberhofer E, van Dijk WJ, Korner R, Olsen JV, Jentsch S, Melchior F, SixmaTK. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat Struct Mol Biol 2005; 12: 264-9.
63. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkBa inhibits NF-kB activation. Mol Cell 1998; 2: 233-9.
64. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitinmediated pathway. Nat Cell Biol 2008; 10: 547-55.
65. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997; 88: 97-107.
66. Matunis MJ, Wu J, Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J Cell Biol 1998; 140: 499-509.
67. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-46.
68. Klug H, Xaver M, Chaugule VK, Koidl S, Mittler G, Klein F, Pichler A. Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae. Mol Cell 2013; 50: 625-36.
69. Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann M, Sixma TK, Pichler A. Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell 2008; 31: 371-82.
70. Praefcke GJ, Hofmann K, Dohmen RJ. SUMO playing tag with ubiquitin. Trends Biochem Sci 2012; 37: 23-31.
71. Streich FC, Jr., Lima CD. Capturing a substrate in an activated RING E3/E2-SUMO complex. Nature 2016; 536: 304-8.
72. Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J 2007; 26: 2797-807.
73. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA 2004; 101: 14373-8.
74. Cappadocia L, Mascle XH, Bourdeau V, Tremblay-Belzile S, Chaker-Margot M, Lussier-Price M, Wada J, Sakaguchi K, Aubry M, Ferbeyre G, Omichinski JG. Structural and functional characterization of the phosphorylation-dependent interaction between PML and SUMO1. Structure 2015; 23: 126-38.
75. Cappadocia L, Pichler A, Lima CD. Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase. Nat Struct Mol Biol 2015; 22: 968-75.
76. Chang CC, Naik MT, Huang YS, Jeng JC, Liao PH, Kuo HY, Ho CC, Hsieh YL, Lin CH, Huang NJ, Naik NM, Kung CC, Lin SY, Chen RH, Chang KS, Huang TH, Shih HM. Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell 2011; 42: 62-74.
77. Capili AD, Lima CD. Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction. J Mol Biol 2007; 369: 608-18.
78. Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse A, Waddell MB, Bjornsti MA, Schulman BA. Structure of a SUMObinding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway. J Mol Biol 2007; 369: 619-30.
79. Liu Q, Jin C, Liao X, Shen Z, Chen DJ, Chen Y. The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1). J Biol Chem 1999; 274: 16979-87.
80. Pilla E, Moller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. J Biol Chem 2012; 287: 4420-9.
81. Danielsen JR, Povlsen LK, Villumsen BH, Streicher W, Nilsson J, Wikstrom M, Bekker-Jensen S, Mailand N. DNA damage-inducible SUMOylation of HERC2 promotes RNF8 binding via a novel SUMO-binding Zinc finger. J Cell Biol 2012; 197: 179-87.
82. Diehl C, Akke M, Bekker-Jensen S, Mailand N, Streicher W, Wikstrom M. Structural Analysis of a Complex between Small Ubiquitin-like Modifier 1 (SUMO1) and the ZZ Domain of CREBbinding Protein (CBP/p300) Reveals a New Interaction Surface on SUMO. J Biol Chem 2016; 291: 12658-72.
83. Eisenhardt N, Chaugule VK, Koidl S, Droescher M, Dogan E, Rettich J, Sutinen P, Imanishi SY, Hofmann K, Palvimo JJ, Pichler A. A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly. Nat Struct Mol Biol 2015; 22: 959-67.
84. Meulmeester E, Kunze M, Hsiao HH, Urlaub H, Melchior F. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol Cell 2008; 30: 610-9.
85. Ouyang J, Shi Y, Valin A, Xuan Y, Gill G. Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol Cell 2009; 34: 145-54.
86. Anamika, Spyracopoulos L. Molecular basis for phosphorylation-dependent SUMO recognition by the DNA repair protein RAP80. J Biol Chem 2016; 291: 4417-28.
87. Mascle XH, Lussier-Price M, Cappadocia L, Estephan P, Raiola L, Omichinski JG, Aubry M. Identification of a noncovalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation. J Biol Chem 2013; 288: 36312-27.
88. Stehmeier P, Muller S. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 2009; 33: 400-9.
89. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. Specification of SUMO1-and SUMO2-interacting motifs. J Biol Chem 2006; 281: 16117-27.
90. Olsen SK, Capili AD, Lu X, Tan DS, Lima CD. Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 2010; 463: 906-12.
91. Desterro JM, Rodriguez MS, Kemp GD, Hay RT. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem 1999; 274: 10618-24.
92. Johnson ES, Schwienhorst I, Dohmen RJ, Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J 1997; 16: 5509-19.
93. Dohmen RJ, Stappen R, McGrath JP, Forrova H, Kolarov J, Goffeau A, Varshavsky A. An essential yeast gene encoding a homolog of ubiquitin-activating enzyme. J Biol Chem 1995; 270: 18099-109.
94. Bossis G, Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol Cell 2006; 21: 349-57.
95. Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, Pelegrin M, Kaoma T, Vallar L, Recher C, Manenti S, Piechaczyk M. The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep 2014; 7: 1815-23.
96. Truong K, Lee TD, Chen Y. Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity. J Biol Chem 2012; 287: 15154-63.
97. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S. A mechanism for inhibiting the SUMO pathway. Mol Cell 2004; 16: 549-61.
98. He X, Riceberg J, Pulukuri SM, Grossman S, Shinde V, Shah P, Brownell JE, Dick L, Newcomb J, Bence N. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation. PLoS One 2015; 10: e0123882.
99. Amelio I, Landre V, Knight RA, Lisitsa A, Melino G, Antonov AV. Polypharmacology of small molecules targeting the ubiquitinproteasome and ubiquitin-like systems. Oncotarget 2015; 6: 9646-56.
100. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438-44.
101. Tong H, Hateboer G, Perrakis A, Bernards R, Sixma TK. Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system. J Biol Chem 1997; 272: 21381-7.
102. Matuschewski K, Hauser HP, Treier M, Jentsch S. Identification of a novel family of ubiquitin-conjugating enzymes with distinct amino-terminal extensions. J Biol Chem 1996; 271: 2789-94.
103. Olsen SK, Lima CD. Structure of a ubiquitin E1-E2 complex: insights to E1-E2 thioester transfer. Mol Cell 2013; 49: 884-96.
104. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005; 9: 769-79.
105. Hayashi T, Seki M, Maeda D, Wang W, Kawabe Y, Seki T, Saitoh H, Fukagawa T, Yagi H, Enomoto T. Ubc9 is essential for viability of higher eukaryotic cells. Exp Cell Res 2002; 280: 212-21.
106. Nowak M, Hammerschmidt M. Ubc9 regulates mitosis and cell survival during zebrafish development. Mol Biol Cell 2006; 17: 5324-36.
107. Seufert W, Futcher B, Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S-and M-phase cyclins. Nature 1995; 373: 78-81.
108. al-Khodairy F, Enoch T, Hagan IM, Carr AM. The Schizosaccharomyces pombe hus5 gene encodes a ubiquitin conjugating enzyme required for normal mitosis. J Cell Sci 1995; 108 (Pt 2): 475-86.
109. Schwarz SE, Matuschewski K, Liakopoulos D, Scheffner M, Jentsch S. The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc Natl Acad Sci USA 1998; 95: 560-4.
110. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002; 108: 109-20.
111. Zhu S, Goeres J, Sixt KM, Bekes M, Zhang XD, Salvesen GS, Matunis MJ. Protection from isopeptidase-mediated deconjugation regulates paralog-selective sumoylation of RanGAP1. Mol Cell 2009; 33: 570-80.
112. Papouli E, Chen S, Davies AA, Huttner D, Krejci L, Sung P, Ulrich HD. Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol Cell 2005; 19: 123-33.
113. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI, Hung CC, Suen CS, Hwang MJ, Chang KS, Maul GG, Shih HM. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 2006; 24: 341-54.
114. Zhu J, Zhu S, Guzzo CM, Ellis NA, Sung KS, Choi CY, Matunis MJ. Small ubiquitin-related modifier (SUMO) binding determines substrate recognition and paralog-selective SUMO modification. J Biol Chem 2008; 283: 29405-15.
115. Takahashi H, Hatakeyama S, Saitoh H, Nakayama KI. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J Biol Chem 2005; 280: 5611-21.
116. Ivanov AV, Peng H, Yurchenko V, Yap KL, Negorev DG, Schultz DC, Psulkowski E, Fredericks WJ, White DE, Maul GG, Sadofsky MJ, Zhou MM, Rauscher FJ 3rd. PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol Cell 2007; 28: 823-37.
117. Guervilly J-H, Takedachi A, Naim V, Scaglione S, Chawhan C, Lovera Y, Despras E, Kuraoka I, Kannouche P, Rosselli F, Gaillard PH. The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. Mol Cell 2015; 57: 123-37.
118. Tomasi ML, Ramani K, Ryoo M. Ubiquitin-conjugating enzyme 9 phosphorylation as a novel mechanism for potentiation of the inflammatory response. Am J Pathol 2016; 186: 2326-36.
119. Hsieh YL, Kuo HY, Chang CC, Naik MT, Liao PH, Ho CC, Huang TC, Jeng JC, Hsu PH, Tsai MD, Huang TH, Shih HM. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response. EMBO J 2013; 32: 791-804.
120. Bencsath KP, Podgorski MS, Pagala VR, Slaughter CA, Schulman BA. Identification of a multifunctional binding site on Ubc9p required for Smt3p conjugation. J Biol Chem 2002; 277: 47938-45.
121. Tatham MH, Kim S, Yu B, Jaffray E, Song J, Zheng J, Rodriguez MS, Hay RT, Chen Y. Role of an N-terminal site of Ubc9 in SUMO-1,-2, and-3 binding and conjugation. Biochemistry 2003; 42: 9959-69.
122. Brzovic PS, Lissounov A, Christensen DE, Hoyt DW, Klevit RE. A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination. Mol Cell 2006; 21: 873-80.
123. McKenna S, Moraes T, Pastushok L, Ptak C, Xiao W, Spyracopoulos L, Ellison MJ. An NMR-based model of the ubiquitin-bound human ubiquitin conjugation complex Mms2.Ubc13. The structural basis for lysine 63 chain catalysis. J Biol Chem 2003; 278: 13151-8.
124. Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. The RanBP2 SUMO E3 ligase is neither HECT-nor RING-type. Nat Struct Mol Biol 2004; 11: 984-91.
125. Reverter D, Lima CD. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 2005; 435: 687-92.
126. Heaton PR, Deyrieux AF, Bian XL, Wilson VG. HPV E6 proteins target Ubc9, the SUMO conjugating enzyme. Virus Res 2011; 158: 199-208.
127. Ribet D, Hamon M, Gouin E, Nahori MA, Impens F, Neyret-Kahn H, Gevaert K, Vandekerckhove J, Dejean A, Cossart P. Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 2010; 464: 1192-5.
128. Mo YY, Moschos SJ. Targeting Ubc9 for cancer therapy. Expert Opin Ther Targets 2005; 9: 1203-16.
129. Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advancedstage melanomas. Oncogene 2007; 26: 4216-25.
130. Wu F, Zhu S, Ding Y, Beck WT, Mo YY. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 2009; 15: 1550-7.
131. Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan J, Qiang B, Peng X. microRNA-214-mediated UBC9 expression in glioma. BMB Rep 2012; 45: 641-6.
132. Koh EH, Chen Y, Bader DA, Hamilton MP, He B, York B, Kajimura S, McGuire SE, Hartig SM. Mitochondrial Activity in Human White Adipocytes Is Regulated by the Ubiquitin Carrier Protein 9/microRNA-30a Axis. J Biol Chem 2016; 291: 24747-24755(1083-351X (Electronic)).
133. Su YF, Yang T, Huang H, Liu LF, Hwang J. Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity. PLoS One 2012; 7: e34250.
134. Novatchkova M, Bachmair A, Eisenhaber B, Eisenhaber F. Proteins with two SUMO-like domains in chromatin-associated complexes: the RENi (Rad60-Esc2-NIP45) family. BMC Bioinformat 2005; 6: 22.
135. Yang K, Moldovan GL, Vinciguerra P, Murai J, Takeda S, D'Andrea AD. Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. Genes Dev 2011; 25: 1847-58.
136. Prudden J, Perry JJ, Arvai AS, Tainer JA, Boddy MN. Molecular mimicry of SUMO promotes DNA repair. Nat Struct Mol Biol 2009; 16: 509-16.
137. Sekiyama N, Arita K, Ikeda Y, Hashiguchi K, Ariyoshi M, Tochio H, Saitoh H, Shirakawa M. Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45. Proteins 2010; 78: 1491-502.
138. Sollier J, Driscoll RF, Castellucci F, Castellucci FF, Foiani M, Foiani MF, Jackson SP, Jackson SF, Branzei D, Branzei D. The Saccharomyces cerevisiae Esc2 and Smc5-6 proteins promote sister chromatid junction-mediated intra-S repair. Mol Biol Cell 2009; 20: 1671-82(1939-4586 (Electronic)).
139. Hashiguchi K, Ozaki M, Kuraoka I, Saitoh H. Establishment of a human cell line stably overexpressing mouse Nip45 and characterization of Nip45 subcellular localization. Biochem Biophys Res Commun 2013; 430: 72-7.
140. Raffa GD, Wohlschlegel J, Yates JR, 3rd, Boddy MN. SUMO-binding motifs mediate the Rad60-dependent response to replicative stress and self-association. J Biol Chem 2006; 281: 27973-81.
141. Johnson ES, Gupta AA. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001; 106: 735-44.
142. Kahyo T, Nishida T, Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell 2001; 8: 713-8.
143. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001; 15: 3088-103.
144. Schmidt D, Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 2002; 99: 2872-7.
145. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 2002; 22: 5222-34.
146. Sapetschnig A, Rischitor G, Braun H, Doll A, Schergaut M, Melchior F, Suske G. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J 2002; 21: 5206-15.
147. Potts PR, Yu H. Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol Cell Biol 2005; 25: 7021-32.
148. Zhao X, Blobel G. A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. Proc Natl Acad Sci USA 2005; 102: 4777-82.
149. Andrews EA, Palecek J, Sergeant J, Taylor E, Lehmann AR, Watts FZ. Nse2, a component of the Smc5-6 complex, is a SUMO ligase required for the response to DNA damage. Mol Cell Biol 2005; 25: 185-96.
150. Yunus AA, Lima CD. Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required for SUMO modification of PCNA. Mol Cell 2009; 35: 669-82.
151. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 11: 861-71.
152. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 2009; 66: 3029-41.
153. Liu B, Mink S, Wong KA, Stein N, Getman C, Dempsey PW, Wu H, Shuai K. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 2004; 5: 891-8.
154. Wong KA, Kim R, Christofk H, Gao J, Lawson G, Wu H. Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol Cell Biol 2004; 24: 5577-86.
155. Roth W, Sustmann C, Kieslinger M, Gilmozzi A, Irmer D, Kremmer E, Turck C, Grosschedl R. PIASy-deficient mice display modest defects in IFN and Wnt signaling. J Immunol 2004; 173: 6189-99.
156. Santti H, Mikkonen L, Anand A, Hirvonen-Santti S, Toppari J, Panhuysen M, Vauti F, Perera M, Corte G, Wurst W, Janne OA, Palvimo JJ. Disruption of the murine PIASx gene results in reduced testis weight. J Mol Endocrinol 2005; 34: 645-54.
157. Tahk S, Liu B, Chernishof V, Wong KA, Wu H, Shuai K. Control of specificity and magnitude of NF-kB and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc Natl Acad Sci USA 2007; 104: 11643-8.
158. Wu CS, Zou L. The SUMO (Small Ubiquitin-like Modifier) Ligase PIAS3 Primes ATR for Checkpoint Activation. J Biol Chem 2016; 291: 279-90.
159. Liu S, Fan Z, Geng Z, Zhang H, Ye Q, Jiao S, Xu X. PIAS3 promotes homology-directed repair and distal non-homologous end joining. Oncol Lett 2013; 6: 1045-8.
160. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009; 462: 935-9.
161. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T, Ng T, Solomon E. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462: 886-90.
162. Zhang C, Yuan X, Yue L, Fu J, Luo L, Yin Z. PIASy interacts with p73alpha and regulates cell cycle in HEK293 cells. Cell Immunol 2010; 263: 235-40.
163. Munarriz E, Barcaroli D, Stephanou A, Townsend PA, Maisse C, Terrinoni A, Neale MH, Martin SJ, Latchman DS, Knight RA, Melino G, De Laurenzi V. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol 2004; 24: 10593-610.
164. Lao M, Shi M, Zou Y, Huang M, Ye Y, Qiu Q, Xiao Y, Zeng S, Liang L, Yang X, Xu H. Protein Inhibitor of Activated STAT3 Regulates Migration, Invasion, and Activation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. J Immunol 2016; 196: 596-606.
165. Castillo-Lluva S, Tatham MH, Jones RC, Jaffray EG, Edmondson RD, Hay RT, Malliri A. SUMOylation of the GTPase Rac1 is required for optimal cell migration. Nat Cell Biol 2010; 12: 1078-85.
166. Leitao BB, Jones MC, Brosens JJ. The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death. FASEB J 2011; 25: 3416-25.
167. Ledsaak M, Bengtsen M, Molvaersmyr AK, Fuglerud BM, Matre V, Eskeland R, Gabrielsen OS. PIAS1 binds p300 and behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO-status. Biochim Biophys Acta 2016; 1859: 705-18.
168. Estruch SB, Graham SA, Deriziotis P, Fisher SE. The languagerelated transcription factor FOXP2 is post-translationally modified with small ubiquitin-like modifiers. Sci Rep 2016; 6: 20911.
169. Siatecka M, Soni S, Planutis A, Bieker JJ. Transcriptional activity of erythroid Kruppel-like factor (EKLF/KLF1) modulated by PIAS3 (protein inhibitor of activated STAT3). J Biol Chem 2015; 290: 9929-40.
170. Beketaev I, Kim EY, Zhang Y, Yu W, Qian L, Wang J. Potentiation of Tbx5-mediated transactivation by SUMO conjugation and protein inhibitor of activated STAT 1 (PIAS1). Int J Biochem Cell Biol 2014; 50: 82-92.
171. Sharrocks AD. PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? Genes Dev 2006; 20: 754-8.
172. Palvimo JJ. PIAS proteins as regulators of small ubiquitinrelated modifier (SUMO) modifications and transcription. Biochem Soc Trans 2007; 35(Pt 6): 1405-8.
173. Brown JR, Conn KL, Wasson P, Charman M, Tong L, Grant K, McFarlane S, Boutell C. The SUMO Ligase Protein Inhibitor of Activated STAT 1 (PIAS1) is a constituent PML-NB protein that contributes to the intrinsic antiviral immune response to herpes simplex virus 1 (HSV-1). J Virol 2016; 90: 5939-52.
174. Conn KL, Wasson P, McFarlane S, Tong L, Brown JR, Grant KG, Domingues P, Boutell C. Novel role for protein inhibitor of activated STAT 4 (PIAS4) in the restriction of herpes simplex virus 1 by the cellular intrinsic antiviral immune response. J Virol 2016; 90: 4807-26.
175. Lin HY, Tsai CH, Lin C, Yeh WL, Tsai CF, Chang PC, Wu LH, Lu DY. Cobalt Protoporphyrin Upregulates Cyclooxygenase-2 Expression Through a Heme Oxygenase-Independent Mechanism. Mol Neurobiol 2016; 53: 4497-508.
176. Trinath J, Holla S, Mahadik K, Prakhar P, Singh V, Balaji KN. The WNT signaling pathway contributes to dectin-1-dependent inhibition of Toll-like receptor-induced inflammatory signature. Mol Cell Biol 2014; 34: 4301-14.
177. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, Yang R, Mink S, Shultz D, Bellone CJ, Loo JA, Shuai K. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007; 129: 903-14.
178. Liu Y, Zhang YD, Guo L, Huang HY, Zhu H, Huang JX, Liu Y, Zhou SR, Dang YJ, Li X, Tang QQ. Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancerbinding protein beta (C/EBPbeta) during adipogenesis. Mol Cell Biol 2013; 33: 4606-17.
179. Tatham MH, Kim S, Jaffray E, Song J, Chen Y, Hay RT. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct Mol Biol 2005; 12: 67-74.
180. Wu J, Matunis MJ, Kraemer D, Blobel G, Coutavas E. Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region. J Biol Chem 1995; 270: 14209-13.
181. Yokoyama N, Hayashi N, Seki T, Pante N, Ohba T, Nishii K, Kuma K, Hayashida T, Miyata T, Aebi U. A giant nucleopore protein that binds Ran/TC4. Nature 1995; 376: 184-8.
182. Chen JW, Barker AR, Wakefield JG. The ran pathway in drosophila melanogaster mitosis. Front Cell Dev Biol 2015; 3: 74.
183. Salina D, Enarson P, Rattner JB, Burke B. Nup358 integrates nuclear envelope breakdown with kinetochore assembly. J Cell Biol 2003; 162: 991-1001.
184. Joseph J, Liu ST, Jablonski SA, Yen TJ, Dasso M. The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr Biol 2004; 14: 611-7.
185. Swaminathan S, Kiendl F, Korner R, Lupetti R, Hengst L, Melchior F. RanGAP1∗SUMO1 is phosphorylated at the onset of mitosis and remains associated with RanBP2 upon NPC disassembly. J Cell Biol 2004; 164: 965-71.
186. Aslanukov A, Bhowmick R, Guruju M, Oswald J, Raz D, Bush RA, Sieving PA, Lu X, Bock CB, Ferreira PA. RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism. PLoS Genet 2006; 2: e177.
187. Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S, Shuai K, Grosschedl R, van Deursen JM. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIa. Cell 2008; 133: 103-15.
188. Clarke DJ, Johnson RT, Downes CS. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 1993; 105 (Pt 2): 563-9.
189. Abascal F, Tress ML, Valencia A. Alternative splicing and cooption of transposable elements: the case of TMPO/LAP2alpha and ZNF451 in mammals. Bioinformatics 2015; 31: 2257-61.
190. Karvonen U, Jaaskelainen T, Rytinki M, Kaikkonen S, Palvimo JJ. ZNF451 is a novel PML body-and SUMO-associated transcriptional coregulator. J Mol Biol 2008; 382: 585-600.
191. Feng Y, Wu H, Xu Y, Zhang Z, Liu T, Lin X, Feng XH. Zinc finger protein 451 is a novel Smad corepressor in transforming growth factor-b signaling. J Biol Chem 2014; 289: 2072-83.
192. Koidl S, Eisenhardt N, Fatouros C, Droescher M, Chaugule VK, Pichler A. The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability. Int J Biochem Cell Biol 2016; 79: 478-87.
193. Gareau JR, Reverter D, Lima CD. Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2. J Biol Chem 2012; 287: 4740-51.
194. Werner A, Flotho A, Melchior F. The RanBP2/RanGAP1∗SUMO1/ Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell 2012; 46: 287-98.
195. Eisenhardt N, Chaugule VK, Pichler A. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation. Methods Mol Biol 2016; 1475: 67-78.
196. Fujiwara K, Hasegawa K, Oka M, Yoneda Y, Yoshikawa K. Terminal differentiation of cortical neurons rapidly remodels RanGAP-mediated nuclear transport system. Genes Cells 2016; 21: 1176-94.
197. Psakhye I, Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell 2012; 151: 807-20.
198. Maison C, Bailly D, Quivy JP, Almouzni G. The methyltransferase Suv39h1 links the SUMO pathway to HP1a marking at pericentric heterochromatin. Nat Commun 2016; 7: 12224.
199. Reindle A, Belichenko I, Bylebyl GR, Chen XL, Gandhi N, Johnson ES. Multiple domains in Siz SUMO ligases contribute to substrate selectivity. J Cell Sci 2006; 119(Pt 22): 4749-57.
200. Pichler A. Analysis of sumoylation. Methods Mol Biol 2008; 446: 131-8.
201. Ritterhoff T, Das H, Hofhaus G, Schroder RR, Flotho A, Melchior F. The RanBP2/RanGAP1∗SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes. Nat Commun 2016; 7: 11482.
202. Swatek KN, Komander D. Ubiquitin modifications. Cell Res 2016; 26: 399-422.
203. Poulsen SL, Hansen RK, Wagner SA, van Cuijk L, van Belle GJ, Streicher W, Wikstrom M, Choudhary C, Houtsmuller AB, Marteijn JA, Bekker-Jensen S, Mailand N. RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response. J Cell Biol 2013; 201: 797-807.
204. Ouyang J, Garner E, Hallet A, Nguyen HD, Rickman KA, Gill G, Smogorzewska A, Zou L. Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. Mol Cell 2015; 57: 108-22.
205. Cheng CH, Lo YH, Liang SS, Ti SC, Lin FM, Yeh CH, Huang HY, Wang TF. SUMO modifications control assembly of synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae. Genes Dev 2006; 20: 2067-81.
206. Srikumar T, Lewicki MC, Costanzo M, Tkach JM, van Bakel H, Tsui K, Johnson ES, Brown GW, Andrews BJ, Boone C, Giaever G, Nislow C, Raught B. Global analysis of SUMO chain function reveals multiple roles in chromatin regulation. J Cell Biol 2013; 201: 145-63.
207. Plechanovova A, Jaffray EG, Tatham MH, Naismith JH, Hay RT. Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature 2012; 489: 115-20.
208. Pruneda JN, Littlefield PJ, Soss SE, Nordquist KA, Chazin WJ, Brzovic PS, Klevit RE. Structure of an E3:E2-Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol Cell 2012; 47: 933-42.
209. Namanja AT, Li YJ, Su Y, Wong S, Lu J, Colson LT, Wu C, Li SS, Chen Y. Insights into high affinity small ubiquitin-like modifier (SUMO) recognition by SUMO-interacting motifs (SIMs) revealed by a combination of NMR and peptide array analysis. J Biol Chem 2012; 287: 3231-40.